Insight into the Mechanism of Intramolecular Inhibition of the Catalytic Activity of Sirtuin 2 (SIRT2)

PLoS One. 2015 Sep 25;10(9):e0139095. doi: 10.1371/journal.pone.0139095. eCollection 2015.

Abstract

Sirtuin 2 (SIRT2) is a NAD+-dependent deacetylase that has been associated with neurodegeneration and cancer. SIRT2 is composed of a central catalytic domain, the structure of which has been solved, and N- and C-terminal extensions that are thought to control SIRT2 function. However structural information of these N- and C-terminal regions is missing. Here, we provide the first full-length molecular models of SIRT2 in the absence and presence of NAD+. We also predict the structural alterations associated with phosphorylation of SIRT2 at S331, a modification that inhibits catalytic activity. Bioinformatics tools and molecular dynamics simulations, complemented by in vitro deacetylation assays, provide a consistent picture based on which the C-terminal region of SIRT2 is suggested to function as an autoinhibitory region. This has the capacity to partially occlude the NAD+ binding pocket or stabilize the NAD+ in a non-productive state. Furthermore, our simulations suggest that the phosphorylation at S331 causes large conformational changes in the C-terminal region that enhance the autoinhibitory activity, consistent with our previous findings that phosphorylation of S331 by cyclin-dependent kinases inhibits SIRT2 catalytic activity. The molecular insight into the role of the C-terminal region in controlling SIRT2 function described in this study may be useful for future design of selective inhibitors targeting SIRT2 for therapeutic applications.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Binding Sites
  • Catalysis
  • Models, Molecular
  • Molecular Dynamics Simulation
  • Phosphorylation
  • Protein Conformation
  • Sirtuin 2 / metabolism*
  • Sirtuin 2 / physiology
  • Sirtuin 2 / ultrastructure
  • Structure-Activity Relationship

Substances

  • Sirt2 protein, mouse
  • Sirtuin 2

Grants and funding

This work was supported by funds from the Interdisciplinary Center for Clinical Research IZKF Aachen (http://www.rwth-aachen.de/cms/root/Forschung/Forschen-an-der-RWTH/Profilbereiche/Medical-Science-Technology-MedST-/~eerv/IZKF/lidx/1/) to BL (fund number: N5-2). The authors gratefully acknowledge the computing time granted by the JARA-HPC Vergabegremium (http://www.jara.org/en/research/jara-hpc/partition/details/details-use-allocation/) to PC (jara0016) and provided on the JARA-HPC Partition part of the supercomputer RWTH Compute Cluster (RCC) at RWTH Aachen University. Jülich Supercomputing Centre (http://www.fz-juelich.de/ias/jsc/EN/Home/home_node.html) provided support in the form of a salary for GR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.